# EDGAR Filing Document

**Accession Number:** 0000001800
**File Stem:** 0001628280-25-035135
**Filing Date:** 2025-7
**Character Count:** 49593
**Document Hash:** a864cf8a4abc916242c92b896c82228c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-035135.hdr.sgml**: 20250717

**ACCESSION NUMBER**: 0001628280-25-035135

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250717

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250717

**DATE AS OF CHANGE**: 20250717

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ABBOTT LABORATORIES
- **CENTRAL INDEX KEY:** 0000001800
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 360698440
- **STATE OF INCORPORATION:** IL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-02189
- **FILM NUMBER:** 251128820

**BUSINESS ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-3500
- **BUSINESS PHONE:** 2246676100

**MAIL ADDRESS:**
- **STREET 1:** 100 ABBOTT PARK ROAD
- **CITY:** ABBOTT PARK
- **STATE:** IL
- **ZIP:** 60064-3500

?xml version='1.0' encoding='ASCII'? abt-20250717

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

_______________________________________________________

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**July 17, 2025**

Date of Report (Date of earliest event reported)

**ABBOTT LABORATORIES**

(Exact name of registrant as specified in charter)

_______________________________________________________

---

| | | |
|:---|:---|:---|
| **Illinois** | **1-2189** | **36-0698440** |
| (State or other Jurisdiction <br>of Incorporation) | (Commission File Number) | (IRS Employer <br>Identification No.) |

---

_______________________________________________________

**100 Abbott Park Road**

**Abbott Park, Illinois 60064-6400**

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: **(224) 667-6100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| ***Title of Each Class*** | **Trading**<br>**Symbol(s)** | **Name of Each Exchange**<br>**on Which Registered** |
| Common Shares, Without Par Value | ABT | New York Stock Exchange<br>Chicago Stock Exchange, Inc. |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 2.02&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition**

On July 17, 2025, Abbott Laboratories announced its results of operations for the second quarter 2025.

Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, fair value adjustments to the contingent consideration related to business acquisitions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax benefit as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott's management internally assesses performance. Abbott's management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott's results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott's management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits**

---

| | |
|:---|:---|
| <u>Exhibit No.</u> | <u>Exhibit</u> |
| <u>[99.1](abt-2025q2xexhibitx991.htm)</u> | <u>[Press Release dated July 17, 2025 (furnished pursuant to Item 2.02).](abt-2025q2xexhibitx991.htm)</u>  |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **ABBOTT LABORATORIES** | **ABBOTT LABORATORIES** |
| Date: July 17, 2025 | By: | /s/ Philip P. Boudreau |
|  |  | Philip P. Boudreau |
|  |  | Executive Vice President, Finance and Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1** 

---

| | |
|:---|:---|
| ![abbottlogoa.jpg](abbottlogoa.jpg) | News Release |

---

Abbott Reports Second-Quarter 2025 Results

**–Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales**<sup>1</sup>

**–Second-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.26**

**–Reported gross margin of 52.7 percent of sales; adjusted gross margin of 57.0 percent, which reflects a 100 basis point increase**

**–Reported operating margin of 18.4 percent of sales; adjusted operating margin of 22.9 percent, which reflects a 100 basis point increase**

ABBOTT PARK, Ill., July 17, 2025 — Abbott today announced financial results for the second quarter ended June 30, 2025.

• Second-quarter sales increased 7.4 percent on a reported basis, 6.9 percent on an organic basis, or 7.5 percent when excluding COVID-19 testing-related sales<sup>1</sup>.

• Second-quarter GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.26, which excludes specified items and reflects double-digit growth compared to the prior year.

• First-half sales increased 5.7 percent on a reported basis, 6.9 percent on an organic basis, or 7.9 percent when excluding COVID-19 testing-related sales<sup>2</sup>.

• Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales.

• Abbott projects full-year 2025 adjusted diluted EPS of $5.10 to $5.20, which reflects double-digit growth at the midpoint.

• In April, Abbott completed enrollment ahead of schedule in its FlexPulse U.S. IDE trial, which is designed to evaluate the TactiFlex<sup>™</sup> Duo Pulsed Field Ablation (PFA) System for treating patients with heart rhythm disorders such as atrial fibrillation (AFib).

• In April, Abbott announced late-breaking data from the AVEIR<sup>™</sup> Conduction System Pacing (CSP) clinical feasibility study. This study was the world's first assessment of a leadless pacemaker delivering conduction pacing, which produces pacing that closely mimics the heart's natural electrical rhythm and represents a new treatment option for people with irregular heart rhythms.

• In May, Abbott announced U.S. Food and Drug Administration (FDA) approval of the company's Tendyne<sup>™</sup> transcatheter mitral valve replacement (TMVR) system, a first-of-its-kind device to help treat people with mitral valve disease.

• Abbott has initiated plans to develop a new cardiovascular device manufacturing facility in the state of Georgia to be completed by 2028.

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline," said Robert B. Ford, chairman and chief executive officer, Abbott. "We see this momentum carrying into 2026."

Page 1 of 20

------

**SECOND-QUARTER BUSINESS OVERVIEW**

*Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect*<sup>®</sup> *product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand the underlying performance of the company as the demand for COVID-19 tests has significantly declined following the transition from a pandemic to endemic phase.*

*Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.* 

**<u>Second Quarter 2025 Results (2Q25)</u>**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Sales 2Q25 ($ in millions)** | **Total Company** | **Nutrition** | **Diagnostics** | **Established Pharmaceuticals** | **Medical Devices** |
| &nbsp;&nbsp;&nbsp;U.S. | 4276 | 957 | 811 |  | 2503 |
| &nbsp;&nbsp;&nbsp;International | 6866 | 1255 | 1362 | 1383 | 2866 |
| Total reported | 11142 | 2212 | 2173 | 1383 | 5369 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **% Change vs. 2Q24** | | | | | |
| &nbsp;&nbsp;&nbsp;U.S. | 8.7 | 2.6 | (0.1) | n/a | 14.6 |
| &nbsp;&nbsp;&nbsp;International | 6.6 | 3.1 | (1.5) | 6.9 | 12.4 |
| **Total reported** | **7.4** | **2.9** | **(1.0)** | **6.9** | **13.4** |
| &nbsp;&nbsp;&nbsp;Impact of foreign exchange | 0.5 | (0.5) | 0.4 | (0.8) | 1.2 |
| **Organic** | **6.9** | **3.4** | **(1.4)** | **7.7** | **12.2** |
| &nbsp;&nbsp;Impact of COVID-19 testing sales <sup>1</sup> | (0.6) |  | (2.2) |  |  |
| **Organic (excluding COVID-19 tests)** | **7.5** | **3.4** | **0.8** | **7.7** | **12.2** |
| **Organic** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 8.7 | 2.6 | (0.1) | n/a | 14.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 5.8 | 4.0 | (2.2) | 7.7 | 10.1 |

---

**<u>First Half 2025 Results (1H25)</u>**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Sales 1H25 ($ in millions)** | **Total Company** | **Nutrition** | **Diagnostics** | **Established Pharmaceuticals** | **Medical Devices** |
| &nbsp;&nbsp;&nbsp;U.S. | 8444 | 1912 | 1682 |  | 4842 |
| &nbsp;&nbsp;&nbsp;International | 13056 | 2446 | 2545 | 2643 | 5422 |
| Total reported | 21500 | 4358 | 4227 | 2643 | 10264 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **% Change vs. 1H24** | | | | | |
| &nbsp;&nbsp;&nbsp;U.S. | 8.5 | 5.6 | (3.5) | n/a | 14.8 |
| &nbsp;&nbsp;&nbsp;International | 3.9 | 1.6 | (4.5) | 4.9 | 9.1 |
| **Total reported** | **5.7** | **3.3** | **(4.1)** | **4.9** | **11.7** |
| &nbsp;&nbsp;&nbsp;Impact of foreign exchange | (1.1) | (1.5) | (0.9) | (2.9) | (0.7) |
| &nbsp;&nbsp;&nbsp;Impact of business exit\* | (0.1) | (0.3) |  |  |  |
| **Organic** | **6.9** | **5.1** | **(3.2)** | **7.8** | **12.4** |
| &nbsp;&nbsp;Impact of COVID-19 testing sales <sup>2</sup> | (1.0) |  | (3.9) |  |  |
| **Organic (excluding COVID-19 tests)** | **7.9** | **5.1** | **0.7** | **7.8** | **12.4** |
| **Organic** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 8.7 | 6.4 | (3.5) | n/a | 14.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 5.8 | 4.1 | (3.0) | 7.8 | 10.3 |

---

Refer to page 16 for a reconciliation of adjusted historical revenue to reported revenue.

\*Reflects the impact of discontinuing the ZonePerfect<sup>®</sup> product line in the Nutrition business in March 2024.

Page 2 of 20

------

**<u>Nutrition</u>**

**<u>Second Quarter 2025 Results (2Q25)</u>**

---

| | | | |
|:---|:---|:---|:---|
| **Sales 2Q25 ($ in millions)** | **Total** | **Pediatric** | **Adult** |
| &nbsp;&nbsp;&nbsp;U.S. | 957 | 587 | 370 |
| &nbsp;&nbsp;&nbsp;International | 1255 | 467 | 788 |
| Total reported | 2212 | 1054 | 1158 |

---

---

| | | | |
|:---|:---|:---|:---|
| **% Change vs. 2Q24** | | | |
| &nbsp;&nbsp;&nbsp;U.S. | 2.6 | 4.2 | 0.2 |
| &nbsp;&nbsp;&nbsp;International | 3.1 | (5.7) | 9.2 |
| **Total reported** | **2.9** | **(0.4)** | **6.1** |
| &nbsp;&nbsp;&nbsp;Impact of foreign exchange | (0.5) | (0.6) | (0.5) |
| **Organic** | **3.4** | **0.2** | **6.6** |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 2.6 | 4.2 | 0.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 4.0 | (4.5) | 9.8 |

---

Worldwide Nutrition sales increased 2.9 percent on a reported basis and 3.4 percent on an organic basis in the second quarter.

Growth in the quarter was led by Adult Nutrition, where global sales increased 6.1 percent on a reported basis and 6.6 percent on an organic basis, led by strong growth of Ensure<sup>®</sup>, Abbott's market-leading complete and balanced nutrition brand, and Glucerna<sup>®</sup>, Abbott's market-leading brand of products designed to meet the nutritional requirements for people with diabetes.

**<u>First Half 2025 Results (1H25)</u>**

---

| | | | |
|:---|:---|:---|:---|
| **Sales 1H25 ($ in millions)** | **Total** | **Pediatric** | **Adult** |
| &nbsp;&nbsp;&nbsp;U.S. | 1912 | 1175 | 737 |
| &nbsp;&nbsp;&nbsp;International | 2446 | 920 | 1526 |
| Total reported | 4358 | 2095 | 2263 |

---

---

| | | | |
|:---|:---|:---|:---|
| **% Change vs. 1H24** | | | |
| &nbsp;&nbsp;&nbsp;U.S. | 5.6 | 9.0 | 0.6 |
| &nbsp;&nbsp;&nbsp;International | 1.6 | (7.0) | 7.7 |
| **Total reported** | **3.3** | **1.3** | **5.3** |
| &nbsp;&nbsp;&nbsp;Impact of foreign exchange | (1.5) | (1.2) | (1.6) |
| &nbsp;&nbsp;&nbsp;Impact of business exit\* | (0.3) |  | (0.7) |
| **Organic** | **5.1** | **2.5** | **7.6** |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 6.4 | 9.0 | 2.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 4.1 | (4.6) | 10.2 |

---

\*Reflects the impact of discontinuing the ZonePerfect<sup>®</sup> product line in the Nutrition business in March 2024.

Page 3 of 20

------

**<u>Diagnostics</u>**

**<u>Second Quarter 2025 Results (2Q25)</u>**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Sales 2Q25 ($ in millions)** | **Total** | **Core Laboratory** | **Molecular** | **Point of Care** | **Rapid Diagnostics** |
| &nbsp;&nbsp;&nbsp;U.S. | 811 | 351 | 35 | 104 | 321 |
| &nbsp;&nbsp;&nbsp;International | 1362 | 1007 | 88 | 44 | 223 |
| Total reported | 2173 | 1358 | 123 | 148 | 544 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **% Change vs. 2Q24** | | | | | |
| &nbsp;&nbsp;&nbsp;U.S. | (0.1) | 7.3 | 5.5 | (2.0) | (7.1) |
| &nbsp;&nbsp;&nbsp;International | (1.5) | 0.5 | (5.6) | (11.9) | (6.1) |
| **Total reported** | **(1.0)** | **2.2** | **(2.7)** | **(5.1)** | **(6.7)** |
| &nbsp;&nbsp;&nbsp;Impact of foreign exchange | 0.4 | 0.6 | 0.7 | 0.1 | 0.1 |
| **Organic** | **(1.4)** | **1.6** | **(3.4)** | **(5.2)** | **(6.8)** |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | (0.1) | 7.3 | 5.5 | (2.0) | (7.1) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | (2.2) | (0.3) | (6.5) | (12.1) | (6.3) |

---

Global Diagnostics sales decreased 1.0 percent on a reported basis, decreased 1.4 percent on an organic basis, and increased 0.8 percent when excluding COVID-19 testing-related sales<sup>1</sup>.

Diagnostics sales growth was impacted by the year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in China.

COVID-19 testing-related sales were $55 million in the quarter, compared to $102 million in the second quarter of the prior year.

Global Core Laboratory Diagnostics sales increased 2.2 percent on a reported basis and increased 1.6 percent on an organic basis. Growth in the quarter was impacted by volume-based procurement programs in China.

**<u>First Half 2025 Results (1H25)</u>**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Sales 1H25 ($ in millions)** | **Total** | **Core Laboratory** | **Molecular** | **Point of Care** | **Rapid Diagnostics** |
| &nbsp;&nbsp;&nbsp;U.S. | 1682 | 683 | 75 | 204 | 720 |
| &nbsp;&nbsp;&nbsp;International | 2545 | 1852 | 170 | 86 | 437 |
| Total reported | 4227 | 2535 | 245 | 290 | 1157 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **% Change vs. 1H24** | | | | | |
| &nbsp;&nbsp;&nbsp;U.S. | (3.5) | 7.2 |  | (0.3) | (12.8) |
| &nbsp;&nbsp;&nbsp;International | (4.5) | (2.4) | (6.1) | (4.5) | (12.3) |
| **Total reported** | **(4.1)** | **0.1** | **(4.4)** | **(1.6)** | **(12.6)** |
| &nbsp;&nbsp;&nbsp;Impact of foreign exchange | (0.9) | (1.2) | (1.0) | (0.4) | (0.6) |
| **Organic** | **(3.2)** | **1.3** | **(3.4)** | **(1.2)** | **(12.0)** |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | (3.5) | 7.2 |  | (0.3) | (12.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;International | (3.0) | (0.7) | (4.9) | (3.3) | (10.7) |

---

Page 4 of 20

------

**<u>Established Pharmaceuticals</u>**

**<u>Second Quarter 2025 Results (2Q25)</u>**

---

| | | | |
|:---|:---|:---|:---|
| **Sales 2Q25 ($ in millions)** | **Total** | **Key Emerging Markets** | **Other** |
| &nbsp;&nbsp;&nbsp;U.S. |  |  |  |
| &nbsp;&nbsp;&nbsp;International | 1383 | 1059 | 324 |
| Total reported | 1383 | 1059 | 324 |

---

---

| | | | |
|:---|:---|:---|:---|
| **% Change vs. 2Q24** | | | |
| &nbsp;&nbsp;&nbsp;U.S. | n/a | n/a | n/a |
| &nbsp;&nbsp;&nbsp;International | 6.9 | 7.3 | 5.9 |
| **Total reported** | **6.9** | **7.3** | **5.9** |
| &nbsp;&nbsp;&nbsp;Impact of foreign exchange | (0.8) | (1.4) | 1.4 |
| **Organic** | **7.7** | **8.7** | **4.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. | n/a | n/a | n/a |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International | 7.7 | 8.7 | 4.5 |

---

Established Pharmaceuticals sales increased 6.9 percent on a reported basis and 7.7 percent on an organic basis in the second quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 7.3 percent on a reported basis and 8.7 percent on an organic basis, led by double-digit growth in several countries across Asia, Latin America and the Middle East.

**<u>First Half 2025 Results (1H25)</u>**

---

| | | | |
|:---|:---|:---|:---|
| **Sales 1H25 ($ in millions)** | **Total** | **Key Emerging Markets** | **Other** |
| &nbsp;&nbsp;&nbsp;U.S. |  |  |  |
| &nbsp;&nbsp;&nbsp;International | 2643 | 2024 | 619 |
| Total reported | 2643 | 2024 | 619 |

---

---

| | | | |
|:---|:---|:---|:---|
| **% Change vs. 1H24** | | | |
| &nbsp;&nbsp;&nbsp;U.S. | n/a | n/a | n/a |
| &nbsp;&nbsp;&nbsp;International | 4.9 | 5.7 | 2.4 |
| **Total reported** | **4.9** | **5.7** | **2.4** |
| &nbsp;&nbsp;&nbsp;Impact of foreign exchange | (2.9) | (3.3) | (1.4) |
| **Organic** | **7.8** | **9.0** | **3.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. | n/a | n/a | n/a |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International | 7.8 | 9.0 | 3.8 |

---

Page 5 of 20

------

**<u>Medical Devices</u>**

**<u>Second Quarter 2025 Results (2Q25)</u>**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Sales 2Q25 ($ in millions)** | **Total** | **Rhythm Management** | **Electro-<br>physiology** | **Heart Failure** | **Vascular** | **Structural Heart** | **Neuro-modulation** | **Diabetes Care** |
| &nbsp;&nbsp;&nbsp;U.S. | 2503 | 340 | 322 | 282 | 283 | 289 | 193 | 794 |
| &nbsp;&nbsp;&nbsp;International | 2866 | 333 | 378 | 86 | 474 | 347 | 61 | 1187 |
| Total reported | 5369 | 673 | 700 | 368 | 757 | 636 | 254 | 1981 |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **% Change vs. 2Q24** | | | | | | | | |
| &nbsp;&nbsp;&nbsp;U.S. | 14.6 | 16.5 | 12.2 | 15.8 | 3.0 | 12.2 | 0.4 | 24.5 |
| &nbsp;&nbsp;&nbsp;International | 12.4 | 5.7 | 10.9 | 11.2 | 5.4 | 13.7 | 20.4 | 17.5 |
| **Total reported** | **13.4** | **10.9** | **11.5** | **14.7** | **4.5** | **13.0** | **4.6** | **20.2** |
| &nbsp;&nbsp;&nbsp;Impact of foreign exchange | 1.2 | 1.1 | 1.2 | 0.7 | 1.0 | 1.3 | 0.3 | 1.7 |
| **Organic** | **12.2** | **9.8** | **10.3** | **14.0** | **3.5** | **11.7** | **4.3** | **18.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 14.6 | 16.5 | 12.2 | 15.8 | 3.0 | 12.2 | 0.4 | 24.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 10.1 | 3.6 | 8.8 | 8.4 | 3.8 | 11.4 | 18.7 | 14.7 |

---

Worldwide Medical Devices sales increased 13.4 percent on a reported basis and 12.2 percent on an organic basis in the second quarter.

Sales growth in the quarter was led by double-digit growth in Diabetes Care, Heart Failure, Structural Heart and Electrophysiology.

Several products contributed to the strong performance, including FreeStyle Libre<sup>®</sup>, Navitor<sup>®</sup>, TriClip<sup>®</sup> and AVEIR<sup>®</sup>.

In Diabetes Care, sales of continuous glucose monitors were $1.9 billion and grew 21.4 percent on a reported basis and 19.6 percent on an organic basis.

**<u>First Half 2025 Results (1H25)</u>**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Sales 1H25 ($ in millions)** | **Total** | **Rhythm Management** | **Electro-<br>physiology** | **Heart Failure** | **Vascular** | **Structural Heart** | **Neuro-modulation** | **Diabetes Care** |
| &nbsp;&nbsp;&nbsp;U.S. | 4842 | 644 | 621 | 544 | 551 | 571 | 369 | 1542 |
| &nbsp;&nbsp;&nbsp;International | 5422 | 614 | 708 | 163 | 916 | 642 | 113 | 2266 |
| Total reported | 10264 | 1258 | 1329 | 707 | 1467 | 1213 | 482 | 3808 |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **% Change vs. 1H24** | | | | | | | | |
| &nbsp;&nbsp;&nbsp;U.S. | 14.8 | 14.4 | 11.7 | 13.2 | 4.2 | 16.3 | (1.1) | 25.7 |
| &nbsp;&nbsp;&nbsp;International | 9.1 | 1.2 | 7.6 | 12.6 | 3.5 | 9.3 | 18.5 | 13.8 |
| **Total reported** | **11.7** | **7.6** | **9.5** | **13.1** | **3.8** | **12.5** | **2.9** | **18.4** |
| &nbsp;&nbsp;&nbsp;Impact of foreign exchange | (0.7) | (0.4) | (0.6) | (0.2) | (0.7) | (0.7) | (0.4) | (0.7) |
| **Organic** | **12.4** | **8.0** | **10.1** | **13.3** | **4.5** | **13.2** | **3.3** | **19.1** |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | 14.8 | 14.4 | 11.7 | 13.2 | 4.2 | 16.3 | (1.1) | 25.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 10.3 | 2.0 | 8.8 | 13.4 | 4.8 | 10.5 | 20.5 | 15.0 |

---

Page 6 of 20

------

**ABBOTT'S FINANCIAL GUIDANCE**

Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales.

Abbott projects full-year 2025 adjusted operating margin to be approximately 23.5% of sales.

Abbott projects full-year 2025 adjusted diluted earnings per share of $5.10 to $5.20 and third-quarter 2025 adjusted diluted earnings per share of $1.28 to $1.32.

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.

**ABBOTT DECLARES 406**<sup>th</sup> **CONSECUTIVE QUARTERLY DIVIDEND**

On June 13, 2025, the board of directors of Abbott declared the company's quarterly dividend of $0.59 per share. Abbott's cash dividend is payable Aug. 15, 2025, to shareholders of record at the close of business on July 15, 2025.

Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

**About Abbott:** 

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

Abbott will live-webcast its second-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

Page 7 of 20

------

**— Private Securities Litigation Reform Act of 1995 —**

**A Caution Concerning Forward-Looking Statements**

*Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2024, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.*

---

| | |
|:---|:---|
| **Abbott Financial:**<br>Michael Comilla, 224-668-1872<br>Tamika McLoughlin, 224-399-5082<br>Randy Blakley, 224-361-7966 | **Abbott Media:**<br>Karen Twigg May, 224-668-2681<br>Kate Dyer, 224-668-9965 |

---

1. In the second quarter of 2025, total worldwide sales were $11.142 billion, total Diagnostics sales were $2.173 billion and COVID-19 testing-related sales were $55 million. In the second quarter of 2024, total worldwide sales were $10.377 billion, total Diagnostics sales were $2.195 billion and COVID-19 testing-related sales were $102 million.

2. In the first half of 2025, total worldwide sales were $21.500 billion, total Diagnostics sales were $4.227 billion and COVID-19 testing-related sales were $139 million. In the first half of 2024, total worldwide sales were $20.341 billion, total Diagnostics sales were $4.409 billion and COVID-19 testing-related sales were $306 million.

Page 8 of 20

------

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Second Quarter Ended June 30, 2025 and 2024

(in millions, except per share data)

(unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2Q25** | **2Q24** | **% Change** | |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Sales | $11142 | $10377 | 7.4 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of products sold, excluding amortization expense | 4854 | 4603 | 5.5 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | 420 | 471 | (10.7) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 725 | 698 | 3.9 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general, and administrative | 3091 | 2936 | 5.3 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Operating Cost and Expenses | 9090 | 8708 | 4.4 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating Earnings | 2052 | 1669 | 23.0 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 50 | 58 | (14.2) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net foreign exchange (gain) loss | (11) | (6) | 55.6 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other (income) expense, net | (137) | 10 | n/m |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Earnings before taxes | 2150 | 1607 | 33.8 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes on earnings | 371 | 305 | 21.3 | 1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Earnings | $1779 | $1302 | 36.7 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Earnings excluding Specified Items, as described below | $2213 | $2003 | 10.5 | 2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted Earnings per Common Share | $1.01 | $0.74 | 36.5 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted Earnings per Common Share,excluding Specified Items, as described below | $1.26 | $1.14 | 10.5 | 2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Average Number of Common Shares OutstandingPlus Dilutive Common Stock Options | 1751 | 1751 |  |  |

---

NOTES:

See tables on page 13 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

Page 9 of 20

------

1)2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2024 Taxes on Earnings includes the recognition of approximately $25 million of net tax expense as a result of the resolution of various tax positions related to prior years.

2)2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $434 million, or $0.25 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.

2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $701 million, or $0.40 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses.

Page 10 of 20

------

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

First Half Ended June 30, 2025 and 2024

(in millions, except per share data)

(unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **1H25** | **1H24** | **% Change** | |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Sales | $21500 | $20341 | 5.7 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of products sold, excluding amortization expense | 9322 | 9066 | 2.8 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | 840 | 943 | (10.8) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 1441 | 1382 | 4.3 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general, and administrative | 6152 | 5895 | 4.4 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Operating Cost and Expenses | 17755 | 17286 | 2.7 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating Earnings | 3745 | 3055 | 22.6 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 99 | 119 | (16.4) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net foreign exchange (gain) loss | (18) | (6) | n/m |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other (income) expense, net | (264) | (101) | n/m |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Earnings before taxes | 3928 | 3043 | 29.1 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes on earnings | 824 | 516 | 59.5 | 1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Earnings | $3104 | $2527 | 22.9 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Earnings excluding Specified Items, as described below | $4132 | $3732 | 10.7 | 2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted Earnings per Common Share | $1.77 | $1.44 | 22.9 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted Earnings per Common Share,excluding Specified Items, as described below | $2.35 | $2.12 | 10.8 | 2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Average Number of Common Shares OutstandingPlus Dilutive Common Stock Options | 1749 | 1750 |  |  |

---

NOTES:

See tables on page 14 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

Page 11 of 20

------

1)2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years.

2)2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.028 billion, or $0.58 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.

2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.205 billion, or $0.68 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses.

Page 12 of 20

------

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

Second Quarter Ended June 30, 2025 and 2024

(in millions, except per share data)

(unaudited)

---

| | | | |
|:---|:---|:---|:---|
| | **2Q25** | **2Q25** | **2Q25** |
| | **As<br>Reported (GAAP)** | **Specified Items** | **As<br>Adjusted** |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible Amortization | $**420** | $(420) | $**—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross Margin | **5868** | 478 | **6346** |
| &nbsp;&nbsp;&nbsp;&nbsp;R&D | **725** | (20) | **705** |
| &nbsp;&nbsp;&nbsp;&nbsp;SG&A | **3091** | (1) | **3090** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other (income) expense, net | **(137)** | (1) | **(138)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Earnings before taxes | **2150** | 500 | **2650** |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes on Earnings | **371** | 66 | **437** |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Earnings | **1779** | 434 | **2213** |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted Earnings per Share | $**1.01** | $0.25 | $**1.26** |

---

Specified items reflect intangible amortization expense of $420 million and other net expenses of $80 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See page 17 for additional details regarding specified items.

---

| | | | |
|:---|:---|:---|:---|
| | **2Q24** | **2Q24** | **2Q24** |
| | **As<br>Reported (GAAP)** | **Specified Items** | **As<br>Adjusted** |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible Amortization | $**471** | $(471) | $**—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross Margin | **5303** | 506 | **5809** |
| &nbsp;&nbsp;&nbsp;&nbsp;R&D | **698** | (41) | **657** |
| &nbsp;&nbsp;&nbsp;&nbsp;SG&A | **2936** | (57) | **2879** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other (income) expense, net | **10** | (145) | **(135)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Earnings before taxes | **1607** | 749 | **2356** |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes on Earnings | **305** | 48 | **353** |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Earnings | **1302** | 701 | **2003** |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted Earnings per Share | $**0.74** | $0.40 | $**1.14** |

---

Specified items reflect intangible amortization expense of $471 million and other net expenses of $278 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See page 18 for additional details regarding specified items.

Page 13 of 20

------

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

First Half Ended June 30, 2025 and 2024

(in millions, except per share data)

(unaudited)

---

| | | | |
|:---|:---|:---|:---|
| | **1H25** | **1H25** | **1H25** |
| | **As<br>Reported (GAAP)** | **Specified Items** | **As<br>Adjusted** |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible Amortization | $**840** | $(840) | $**—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross Margin | **11338** | 926 | **12264** |
| &nbsp;&nbsp;&nbsp;&nbsp;R&D | **1441** | (47) | **1394** |
| &nbsp;&nbsp;&nbsp;&nbsp;SG&A | **6152** | (11) | **6141** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other (income) expense, net | **(264)** | (36) | **(300)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Earnings before taxes | **3928** | 1020 | **4948** |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes on Earnings | **824** | (8) | **816** |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Earnings | **3104** | 1028 | **4132** |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted Earnings per Share | $**1.77** | $0.58 | $**2.35** |

---

Specified items reflect intangible amortization expense of $840 million and other net expenses of $180 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See page 19 for additional details regarding specified items.

---

| | | | |
|:---|:---|:---|:---|
| | **1H24** | **1H24** | **1H24** |
| | **As<br>Reported (GAAP)** | **Specified Items** | **As<br>Adjusted** |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible Amortization | $**943** | $(943) | $**—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross Margin | **10332** | 1024 | **11356** |
| &nbsp;&nbsp;&nbsp;&nbsp;R&D | **1382** | (62) | **1320** |
| &nbsp;&nbsp;&nbsp;&nbsp;SG&A | **5895** | (91) | **5804** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other (income) expense, net | **(101)** | (171) | **(272)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Earnings before taxes | **3043** | 1348 | **4391** |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes on Earnings | **516** | 143 | **659** |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Earnings | **2527** | 1205 | **3732** |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted Earnings per Share | $**1.44** | $0.68 | $**2.12** |

---

Specified items reflect intangible amortization expense of $943 million and other net expenses of $405 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See page 20 for additional details regarding specified items.

Page 14 of 20

------

A reconciliation of the second-quarter tax rates for 2025 and 2024 is shown below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2Q25** | **2Q25** | **2Q25** | |
| ($ in millions) | **Pre-Tax<br>Income** | **Taxes on<br>Earnings** | **Tax<br>Rate** |  |
| **As reported (GAAP)** | $**2150** | $**371** | **17.3%** | 1) |
| Specified items | 500 | 66 |  |  |
| **Excluding specified items** | $**2650** | $**437** | **16.5%** |  |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2Q24** | **2Q24** | **2Q24** | |
| ($ in millions) | **Pre-Tax<br>Income** | **Taxes on<br>Earnings** | **Tax<br>Rate** |  |
| **As reported (GAAP)** | $**1607** | $**305** | **19.0%** | 2) |
| Specified items | 749 | 48 |  |  |
| **Excluding specified items** | $**2356** | $**353** | **15.0%** |  |

---

1)2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)2024 Taxes on Earnings includes the recognition of approximately $25 million of net tax expense as a result of the resolution of various tax positions related to prior years.

A reconciliation of the year-to-date tax rates for 2025 and 2024 is shown below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **1H25** | **1H25** | **1H25** | |
| ($ in millions) | **Pre-Tax<br>Income** | **Taxes on<br>Earnings** | **Tax<br>Rate** |  |
| **As reported (GAAP)** | $**3928** | $**824** | **21.0%** | 3) |
| Specified items | 1020 | (8) |  |  |
| **Excluding specified items** | $**4948** | $**816** | **16.5%** |  |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **1H24** | **1H24** | **1H24** | |
| ($ in millions) | **Pre-Tax<br>Income** | **Taxes on<br>Earnings** | **Tax<br>Rate** |  |
| **As reported (GAAP)** | $**3043** | $**516** | **17.0%** | 4) |
| Specified items | 1348 | 143 |  |  |
| **Excluding specified items** | $**4391** | $**659** | **15.0%** |  |

---

3)2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

4)2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years.

Page 15 of 20

------

Abbott Laboratories and Subsidiaries

Non-GAAP Revenue Reconciliation

First Half Ended June 30, 2025 and 2024

($ in millions)

(unaudited)

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | 1H25 | 1H24 | 1H24 | 1H24 | % Change vs. 1H24 | % Change vs. 1H24 | % Change vs. 1H24 |
| | | | | | | Non-GAAP | Non-GAAP |
| | Abbott Reported | Abbott Reported | Impact from business exit (a) | Adjusted Revenue | Reported | Adjusted | Organic |
| Total Company | 21500 | 20341 | (13) | 20328 | 5.7 | 5.8 | 6.9 |
| &nbsp;&nbsp;&nbsp;U.S. | 8444 | 7780 | (13) | 7767 | 8.5 | 8.7 | 8.7 |
| &nbsp;&nbsp;&nbsp;Intl | 13056 | 12561 |  | 12561 | 3.9 | 3.9 | 5.8 |
| Total Nutrition | 4358 | 4218 | (13) | 4205 | 3.3 | 3.6 | 5.1 |
| &nbsp;&nbsp;&nbsp;U.S. | 1912 | 1811 | (13) | 1798 | 5.6 | 6.4 | 6.4 |
| &nbsp;&nbsp;&nbsp;Intl | 2446 | 2407 |  | 2407 | 1.6 | 1.6 | 4.1 |
| Adult Nutrition | 2263 | 2150 | (13) | 2137 | 5.3 | 6.0 | 7.6 |
| &nbsp;&nbsp;&nbsp;U.S. | 737 | 733 | (13) | 720 | 0.6 | 2.4 | 2.4 |
| &nbsp;&nbsp;&nbsp;Intl | 1526 | 1417 |  | 1417 | 7.7 | 7.7 | 10.2 |

---

(a) Reflects the impact of discontinuing the ZonePerfect<sup>®</sup> product line in the Nutrition business in March 2024.

Page 16 of 20

------

Abbott Laboratories and Subsidiaries

Details of Specified Items

Second Quarter Ended June 30, 2025

(in millions, except per share data)

(unaudited)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Acquisition or<br>Divestiture-<br>related (a) | Restructuring<br>and Cost<br>Reduction<br>Initiatives (b) | Intangible<br>Amortization | Other (c) | Total<br>Specifieds |
| Gross Margin | $1 | $55 | $420 | $2 | $478 |
| R&D |  | (7) |  | (13) | (20) |
| SG&A | (3) | 1 |  | 1 | (1) |
| Other (income) expense, net | (1) |  |  |  | (1) |
| Earnings before taxes | $5 | $61 | $420 | $14 | 500 |
| Taxes on Earnings (d) |  |  |  |  | 66 |
| Net Earnings |  |  |  |  | $434 |
| Diluted Earnings per Share |  |  |  |  | $0.25 |

---

The table above provides additional details regarding the specified items described on page 13.

a) Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.

b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c) Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d) Reflects the net tax benefit associated with the specified items and the recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Page 17 of 20

------

Abbott Laboratories and Subsidiaries

Details of Specified Items

Second Quarter Ended June 30, 2024

(in millions, except per share data)

(unaudited)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Acquisition or<br>Divestiture-<br>related (a) | Restructuring<br>and Cost<br>Reduction<br>Initiatives (b) | Intangible<br>Amortization | Other (c) | Total<br>Specifieds |
| Gross Margin | $1 | $32 | $471 | $2 | $506 |
| R&D | (1) | 1 |  | (41) | (41) |
| SG&A | (11) | (10) |  | (36) | (57) |
| Other (income) expense, net | (147) |  |  | 2 | (145) |
| Earnings before taxes | $160 | $41 | $471 | $77 | 749 |
| Taxes on Earnings (d) |  |  |  |  | 48 |
| Net Earnings |  |  |  |  | $701 |
| Diluted Earnings per Share |  |  |  |  | $0.40 |

---

The table above provides additional details regarding the specified items described on page 13.

a) Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.

b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c) Other includes incremental costs to comply with the MDR and IVDR requirements for previously approved products and an intangible asset impairment charge.

d) Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years.

Page 18 of 20

------

Abbott Laboratories and Subsidiaries

Details of Specified Items

First Half Ended June 30, 2025

(in millions, except per share data)

(unaudited)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Acquisition or<br>Divestiture-<br>related (a) | Restructuring<br>and Cost<br>Reduction<br>Initiatives (b) | Intangible<br>Amortization | Other (c) | Total<br>Specifieds |
| Gross Margin | $1 | $81 | $840 | $4 | $926 |
| R&D | (1) | (23) |  | (23) | (47) |
| SG&A | (6) | (6) |  | 1 | (11) |
| Other (income) expense, net | (25) |  |  | (11) | (36) |
| Earnings before taxes | $33 | $110 | $840 | $37 | 1020 |
| Taxes on Earnings (d) |  |  |  |  | (8) |
| Net Earnings |  |  |  |  | $1028 |
| Diluted Earnings per Share |  |  |  |  | $0.58 |

---

The table above provides additional details regarding the specified items described on page 14.

a) Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.

b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c) Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments.

d) Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Page 19 of 20

------

Abbott Laboratories and Subsidiaries

Details of Specified Items

First Half Ended June 30, 2024

(in millions, except per share data)

(unaudited)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Acquisition or<br>Divestiture-<br>related (a) | Restructuring<br>and Cost<br>Reduction<br>Initiatives (b) | Intangible<br>Amortization | Other (c) | Total<br>Specifieds |
| Gross Margin | $2 | $74 | $943 | $5 | $1024 |
| R&D | (4) | (1) |  | (57) | (62) |
| SG&A | (25) | (19) |  | (47) | (91) |
| Other (income) expense, net | (135) |  |  | (36) | (171) |
| Earnings before taxes | $166 | $94 | $943 | $145 | 1348 |
| Taxes on Earnings (d) |  |  |  |  | 143 |
| Net Earnings |  |  |  |  | $1205 |
| Diluted Earnings per Share |  |  |  |  | $0.68 |

---

The table above provides additional details regarding the specified items described on page 14.

a) Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.

b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c) Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment and intangible asset impairments.

d) Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years.

Page 20 of 20